Efficacy of HCV Treatment in a Large Clinical Cohort From the English National HCV Registry

April 10-14, 2019; Vienna, Austria
Large observational study reported variations in DAA efficacy among patients with genotype 3 HCV and compensated cirrhosis.
Format: Microsoft PowerPoint (.ppt)
File Size: 185 KB
Released: April 16, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by:
AbbVie
Gilead Sciences

Related Content

Download free expert-authored slides on the clinical interplay of HCV and COVID-19 coinfection and the impact of the COVID-19 pandemic on access to HCV care and treatment

Ricardo Franco, MD Stacey Trooskin, MD, PhD Released: October 7, 2020

Gain experts insight with this CCO commentary on key hepatitis C elimination studies presented at the Digital International Liver Conference 2020

Nancy Reau, MD Released: October 2, 2020

Downloadable slides from CCO expert, Dr. Alain H. Litwin, on integrating HCV and HIV prevention and care strategies into addiction care settings

Alain H. Litwin, MD Released: September 18, 2020

Dr. Stefan Zeuzem discusses new viral hepatitis data reported at the 2020 Digital International Liver Congress, in the CCO Infectious Disease podcast

Stefan Zeuzem, MD Released: September 14, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue